Spinal Muscular Atrophy: Disease Mechanisms and Therapy

Charlotte J. Sumner(Johns Hopkins University), Chien -Ping Ko(University of Southern California), Sergey Paushkin(NKT Therapeutics (United States))

Unknown

November 4, 2016

Cited by 63

Related Papers

CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis

|Journal of Neurology Neurosurgery & Psychiatry|2014|342

Valproic acid increases SMN levels in spinal muscular atrophy patient cells

|Annals of Neurology|2003|288

Overexpression of IGF-1 in Muscle Attenuates Disease in a Mouse Model of Spinal and Bulbar Muscular Atrophy

|Neuron|2009|215

Distal spinal and bulbar muscular atrophy caused by dynactin mutation

|Annals of Neurology|2005|200

Age-dependent SMN expression in disease-relevant tissue and implications for SMA treatment

|Journal of Clinical Investigation|2019|190